These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 37287044

  • 21. Emergence of eravacycline heteroresistance in carbapenem-resistant Acinetobacter baumannii isolates in China.
    Li YT, Chen XD, Guo YY, Lin SW, Wang MZ, Xu JB, Wang XH, He GH, Tan XX, Zhuo C, Lin ZW.
    Front Cell Infect Microbiol; 2024; 14():1356353. PubMed ID: 38601741
    [Abstract] [Full Text] [Related]

  • 22. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii.
    Principe L, D'Arezzo S, Capone A, Petrosillo N, Visca P.
    Ann Clin Microbiol Antimicrob; 2009 May 21; 8():18. PubMed ID: 19460166
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Prevalence and Clinical Consequences of Colistin Heteroresistance and Evolution into Full Resistance in Carbapenem-Resistant Acinetobacter baumannii.
    Kon H, Hameir A, Nutman A, Temkin E, Keren Paz A, Lellouche J, Schwartz D, Weiss DS, Kaye KS, Daikos GL, Skiada A, Durante-Mangoni E, Dishon Benattar Y, Yahav D, Daitch V, Bernardo M, Iossa D, Friberg LE, Theuretzbacher U, Leibovici L, Dickstein Y, Pollak D, Mendelsohn S, Paul M, Carmeli Y.
    Microbiol Spectr; 2023 Jun 15; 11(3):e0509322. PubMed ID: 37219426
    [Abstract] [Full Text] [Related]

  • 26. Molecular Mechanisms of Colistin Resistance Among Pandrug-Resistant Isolates of Acinetobacter baumannii with High Case-Fatality Rate in Intensive Care Unit Patients.
    Haeili M, Kafshdouz M, Feizabadi MM.
    Microb Drug Resist; 2018 Nov 15; 24(9):1271-1276. PubMed ID: 29590004
    [Abstract] [Full Text] [Related]

  • 27. Trend of extensively drug-resistant Acinetobacter baumannii and the remaining therapeutic options: a multicenter study in Tehran, Iran over a 3-year period.
    Jasemi S, Douraghi M, Adibhesami H, Zeraati H, Rahbar M, Boroumand MA, Aliramezani A, Ghourchian S, Mohammadzadeh M.
    Lett Appl Microbiol; 2016 Dec 15; 63(6):466-472. PubMed ID: 27626896
    [Abstract] [Full Text] [Related]

  • 28. In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii.
    Ni W, Cui J, Liang B, Cai Y, Bai N, Cai X, Wang R.
    J Antibiot (Tokyo); 2013 Dec 15; 66(12):705-8. PubMed ID: 23981963
    [Abstract] [Full Text] [Related]

  • 29. In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group.
    Arroyo LA, Mateos I, González V, Aznar J.
    Antimicrob Agents Chemother; 2009 Mar 15; 53(3):1295-6. PubMed ID: 19075049
    [No Abstract] [Full Text] [Related]

  • 30. Detection of colistin heteroresistance in Acinetobacter baumannii from blood and respiratory isolates.
    Srinivas P, Hunt LN, Pouch SM, Thomas K, Goff DA, Pancholi P, Balada-Llasat JM, Bauer KA.
    Diagn Microbiol Infect Dis; 2018 Jun 15; 91(2):194-198. PubMed ID: 29482871
    [Abstract] [Full Text] [Related]

  • 31. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii.
    Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, Liolios L.
    Antimicrob Agents Chemother; 2006 Sep 15; 50(9):2946-50. PubMed ID: 16940086
    [Abstract] [Full Text] [Related]

  • 32. Resistance and Heteroresistance to Colistin in Pseudomonas aeruginosa Isolates from Wenzhou, China.
    Lin J, Xu C, Fang R, Cao J, Zhang X, Zhao Y, Dong G, Sun Y, Zhou T.
    Antimicrob Agents Chemother; 2019 Oct 15; 63(10):. PubMed ID: 31383654
    [Abstract] [Full Text] [Related]

  • 33. A novel mutation in pmrB mediates colistin resistance during therapy of Acinetobacter baumannii.
    Dahdouh E, Gómez-Gil R, Sanz S, González-Zorn B, Daoud Z, Mingorance J, Suárez M.
    Int J Antimicrob Agents; 2017 Jun 15; 49(6):727-733. PubMed ID: 28438568
    [Abstract] [Full Text] [Related]

  • 34. Emergence of rifampicin, tigecycline, and colistin-resistant Acinetobacter baumannii in Iran; spreading of MDR strains of novel International Clone variants.
    Bahador A, Taheri M, Pourakbari B, Hashemizadeh Z, Rostami H, Mansoori N, Raoofian R.
    Microb Drug Resist; 2013 Oct 15; 19(5):397-406. PubMed ID: 23768166
    [Abstract] [Full Text] [Related]

  • 35. Colistin heteroresistance in Acinetobacter spp.: systematic review and meta-analysis of the prevalence and discussion of the mechanisms and potential therapeutic implications.
    Karakonstantis S, Saridakis I.
    Int J Antimicrob Agents; 2020 Aug 15; 56(2):106065. PubMed ID: 32599229
    [Abstract] [Full Text] [Related]

  • 36. Comparative assessment of antimicrobial susceptibility testing for tigecycline and colistin against Acinetobacter baumannii clinical isolates, including multidrug-resistant isolates.
    Piewngam P, Kiratisin P.
    Int J Antimicrob Agents; 2014 Nov 15; 44(5):396-401. PubMed ID: 25442358
    [Abstract] [Full Text] [Related]

  • 37. A systematic review of implications, mechanisms, and stability of in vivo emergent resistance to colistin and tigecycline in Acinetobacter baumannii.
    Karakonstantis S.
    J Chemother; 2021 Feb 15; 33(1):1-11. PubMed ID: 32677578
    [Abstract] [Full Text] [Related]

  • 38. In vitro synergistic antimicrobial activity of a combination of meropenem, colistin, tigecycline, rifampin, and ceftolozane/tazobactam against carbapenem-resistant Acinetobacter baumannii.
    Ju YG, Lee HJ, Yim HS, Lee MG, Sohn JW, Yoon YK.
    Sci Rep; 2022 May 09; 12(1):7541. PubMed ID: 35534512
    [Abstract] [Full Text] [Related]

  • 39. Synergistic activities of colistin combined with other antimicrobial agents against colistin-resistant Acinetobacter baumannii clinical isolates.
    Almutairi MM.
    PLoS One; 2022 May 09; 17(7):e0270908. PubMed ID: 35830449
    [Abstract] [Full Text] [Related]

  • 40. Characterisation of successive Acinetobacter baumannii isolates from a deceased haemophagocytic lymphohistiocytosis patient.
    Choi HJ, Kil MC, Choi JY, Kim SJ, Park KS, Kim YJ, Ko KS.
    Int J Antimicrob Agents; 2017 Jan 09; 49(1):102-106. PubMed ID: 27842758
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.